Will the USMCA IP chapter increase spending on medicines?
As parties to the United States-Mexico-Canada Agreement (USMCA), Canada and Mexico have agreed to adopt important intellectual property protections for biologic medicines.
How Innovators Are Solving Global Health Challenges
The Innovate4Health project tells the exciting story of people who are solving the world’s biggest health challenges through innovation.
Patent linkage system crucial for knowledge economy
Taiwan’s downward revision of its growth and export forecasts last month confirms the need to diversify from its main business of exporting manufactured commodities.
专利扣合机制之前景
对知识产权（IP）的大力保护对生物制药创新十分重要。保护知识产权能够为疾病预防、诊断和治疗吸引和维持长期投资创造激励和商业确定性。然而，没有有效的执法，知识产权将价值甚微。
The Promise of Patent Linkage
Countries that want to build an innovation driven knowledge-economy should embrace patent linkage, writes Jack Ellis
IP ambivalence risks Europe’s competitiveness
In a world where economic growth increasingly depends on “intangible” products and services based on human know-how, knowledge and creativity, only those countries that have the right policy attitude to innovation will thrive. In addition to skills, regulation and tax policy, intellectual property rights are
Argentina’s innovative solution to an ancient childbirth problem
Mr Odon’s imagination allowed him to look at an old problem in new way. But the long road to commercialisation has required cooperation, investment and perspiration — and that is where intellectual property rights have been key.
Knowledge economy must be at the heart of the WTO reform agenda
To ensure modern trade and investment can continue on non-discriminatory terms for everyone, the WTO should put Intellectual property first.
Copy or Compete? How India’s patent law harms its own drug industry’s ability to innovate
Section 3(d) of India’s patent law may be putting India at a competitive disadvantage. The data presented in this research note shows it is preventing Indian generic pharmaceutical companies from developing new formulations, compositions, and combinations of existing medicines, which they instead undertake and commercialise abroad.